Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers
Elona Cekani, Samantha Epistolio, Giulia Dazio, et al.
Cancers (2022) Vol. 14, Iss. 17, pp. 4103-4103
Open Access | Times Cited: 19

Showing 19 citing articles:

Unveiling the role of KRAS in tumor immune microenvironment
Miao Xu, Xing Zhao, Ti Wen, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116058-116058
Open Access | Times Cited: 24
Genetic differences between smokers and never-smokers with lung cancer
Piotr Kuśnierczyk
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
A novel intranasal peptide vaccine inhibits non-small cell lung cancer with KRAS mutation
Su He Wang, Zhengyi Cao, Mohammad Farazuddin, et al.
Cancer Gene Therapy (2024)
Closed Access | Times Cited: 4
Vistas in Non-Small Cell Lung Cancer (NSCLC) Treatment: of Kinome and Signaling Networks
Dimitrios J. Stravopodis, Kostas A. Papavassiliou, Athanasios G. Papavassiliou
International Journal of Biological Sciences (2023) Vol. 19, Iss. 7, pp. 2002-2005
Open Access | Times Cited: 10
Prognostic and immunological characteristics of CDK1 in lung adenocarcinoma: A systematic analysis
Qingwu Du, Wenting Liu, Ting Mei, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 8
The research advances in Kirsten rat sarcoma viral oncogene homolog (KRAS)-related cancer during 2013 to 2022: a scientometric analysis
Yujie Huang, Daitian Zheng, Zhongming Zhou, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Non-coding RNAs and regulation of the PI3K signaling pathway in lung cancer: recent insights and potential clinical applications
Mehrdad Hashemi, Asal Abolghasemi Fard, Bita Pakshad, et al.
Non-coding RNA Research (2024) Vol. 11, pp. 1-21
Open Access | Times Cited: 1
Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review
S Berenice Urtecho, Leonardo Provenzano, Andrea Spagnoletti, et al.
Lung Cancer (2024) Vol. 199, pp. 108051-108051
Closed Access | Times Cited: 1
Idiopathic pulmonary fibrosis and lung cancer: targeting the complexity of the pharmacological interconnection
Fabio Massimo Perrotta, Vittorio Chino, Valentino Allocca, et al.
Expert Review of Respiratory Medicine (2022) Vol. 16, Iss. 10, pp. 1043-1055
Closed Access | Times Cited: 6
FoxA1/2-dependent epigenomic reprogramming drives lineage switching in lung adenocarcinoma
Katherine Gillis, Walter Orellana, Emily Wilson, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Construction of the Interaction Network of Hub Genes in the Progression of Barrett’s Esophagus to Esophageal Adenocarcinoma
Kai Li, Peipei Duan, Haifa He, et al.
Journal of Inflammation Research (2023) Vol. Volume 16, pp. 1533-1551
Open Access | Times Cited: 2
Exploring Covalent Bond Formation at Tyr‐82 for Inhibition of Ral GTPase Activation
Alexander D. Landgraf, I‐Ju Yeh, Mona K. Ghozayel, et al.
ChemMedChem (2023) Vol. 18, Iss. 16
Open Access | Times Cited: 2
Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
Parneet Cheema, Shantanu Banerji, Normand Blais, et al.
Current Oncology (2023) Vol. 30, Iss. 7, pp. 6473-6496
Open Access | Times Cited: 2
Enhancing an Oxidative “Trojan Horse” Action of Vitamin C with Arsenic Trioxide for Effective Suppression of KRAS-Mutant Cancers: A Promising Path at the Bedside
Agata Burska, Bayansulu Ilyassova, Aruzhan Dildabek, et al.
Cells (2022) Vol. 11, Iss. 21, pp. 3454-3454
Open Access | Times Cited: 4
Integrative bioinformatics analysis reveals ECM and nicotine-related genes in both LUAD and LUSC, but different lung fibrosis-related genes are involved in LUAD and LUSC
Marzyeh Alipour, Mehdi Moghanibashi, Sirous Naeimi, et al.
Nucleosides Nucleotides & Nucleic Acids (2024) Vol. 43, Iss. 9, pp. 915-934
Closed Access
Global research trends in immunotherapy for non-small cell lung cancer patients with KRAS mutations: a bibliometric analysis
Hanyu Shen, Chunxiao Li
Frontiers in Oncology (2024) Vol. 14
Open Access
FoxA1/2-dependent epigenomic reprogramming drives lineage switching in lung adenocarcinoma
Katherine Gillis, Walter Orellana, Emily Wilson, et al.
Developmental Cell (2024)
Open Access
Novel 1,4-Dihydropyrido[2,3-B]Pyrazine-2,3-Dione Derivatives for Treating Cancer and Other Disorders Associated with KRAS Activity
Surya K. De
Anti-Cancer Agents in Medicinal Chemistry (2022) Vol. 23, Iss. 8, pp. 979-980
Closed Access | Times Cited: 1
Identification of Specific Genes for Adenocarcinoma and Squamous Cell of Lung Carcinoma by Bioinformatics Analysis
Marzyeh Alipour, Mehdi Moghanibashi, Sirous Naeimi
Research Square (Research Square) (2023)
Open Access
Page 1

Scroll to top